ALT-946
ALT-946 is an orally active inhibitor of the advanced glycation end product (AGE) formation pathway. ALT-946 blocks the formation of AGE-protein cross-links, reduces the accumulation of AGE in renal tissues, alleviates increased albuminuria and elevated glomerular filtration rate, prevents glomerulosclerosis, ameliorates medullary tubulointerstitial lesions, and reduces cortical tubular degeneration. ALT-946 can be used in research related to diabetic nephropathy and diabetic cardiovascular diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 192511-71-0
- 分子式: C5H14ClN5O
- 分子量:195.65
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
ALT-946 (0.1-30.0 mM) potently inhibits AGE-BSA cross-linking to rat tail tendon collagen in vitro with an IC50 of 3.4 mM[1].
ALT-946 potently inhibits AGE-protein cross-linking in an in vitro purified protein system[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
ALT-946 (1 g/L; p.o.; daily; 32 weeks or 16 weeks delayed) confers renoprotective effects in streptozotocin-induced diabetic Sprague Dawley rats, including attenuation of hyperfiltration, prevention of albuminuria, and inhibition of glomerular AGE accumulation[1].
ALT-946 (1 g/L; p.o.; daily; 12 weeks) confers renoprotection in hypertensive transgenic (mREN-2)27 rats with streptozotocin-induced diabetic nephropathy, reducing albumin excretion rate by 250%, normalizing glomerulosclerosis, improving medullary pathology, and reducing cortical tubular degeneration and renal AGE accumulation without altering blood pressure[3].
ALT-946 (1 g/L; p.o.; daily; 12 weeks) has no measurable effect on renal function, histopathology, or AGE levels in healthy nondiabetic transgenic (mREN-2)27 rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats (male, ~200 g, streptozotocin-induced diabetic)[1]
-
Dosage:0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 8 weeks
-
Result:Normalized RBC-IgG levels completely in diabetic rats at 0.03 mg/kg.
-
Animal Model:Sprague Dawley rats (male, 200-250 g, streptozotocin-induced diabetic)[1]
-
Dosage:1 g/L (continuous 32 weeks); 1 g/L (delayed 16 weeks)
-
Administration:p.o.; daily; 32 weeks; p.o.; daily; 16 weeks (delayed from week 16 to 32)
-
Result:Did not affect body weight, glycaemic control, or systolic blood pressure in diabetic rats.
Attenuated the diabetes-associated increase in glomerular filtration rate.
Prevented the development of diabetes-associated albuminuria.
Reduced glomerular AGE staining to levels similar to non-diabetic control rats.
-
Animal Model:(mREN-2)27 (female, 6 weeks old, streptozotocin-induced diabetic nephropathy)[3]
-
Dosage:1 g/L
-
Administration:p.o.; daily; 12 weeks
-
Result:Reduced the diabetes-induced increase in albumin excretion rate by 250%.
Lowered glomerulosclerotic index to nondiabetic control levels.
Improved medullary tubulointerstitial collagen deposition to a similar extent as aminoguanidine.
Reduced cortical tubular degeneration to a greater degree than aminoguanidine, lowering the number of degenerated tubules per field compared to untreated diabetic rats.
Reduced increased glomerular and tubulointerstitial AGE immunolabeling in diabetic rats to near nondiabetic levels.
Did not alter diabetes-induced increases in kidney weight or glomerular filtration rate.
Did not affect systolic blood pressure or body weight in either nondiabetic or diabetic rats.
-
Animal Model:(mREN-2)27 (female, 6 weeks old)[3]
-
Dosage:1 g/L
-
Administration:p.o.; daily; 12 weeks
-
Result:Showed no effect on body weight, kidney weight, systolic blood pressure, glomerular filtration rate, or albumin excretion rate.
Did not alter renal histology, glomerulosclerotic index, cortical tubular morphology, or AGE immunolabeling, all remaining consistent with untreated nondiabetic controls.
化学情報
-
CAS 番号 192511-71-0
-
分子量 195.65
-
分子式 C5H14ClN5O
-
SMILES
O=C(C)NCCNC(NN)=N.Cl
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- ALT-946
- 192511-71-0
- ALT946
- ALT 946
- Biochemical Assay Reagents
- rat tail tendon collagen
- diabetic cardiovascular disease
- streptozotocin-induced diabetic Lewis rats
- renal tissues
- diabetic nephropathy
- glomerulosclerosis
- advanced glycation end-product
- albuminuria
- glomerular filtration rate
- nitric oxide synthase
- Inhibitor
- inhibitor
- inhibit